<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04479241</url>
  </required_header>
  <id_info>
    <org_study_id>PVSRIPO CPI rGBM 101</org_study_id>
    <nct_id>NCT04479241</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>A Phase 1, Open-label, Single-arm Study Evaluating the Safety and Tolerability of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istari Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istari Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 single arm trial in patients with rGBM will characterize the safety,
      tolerability and initial efficacy of PVSRIPO intratumoral infusion followed by intravenous
      pembrolizumab 14 to 28 days later, and every 3 weeks, thereafter.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>24 months</time_frame>
    <description>Assess safety and tolerability of PVSRIPO followed by pembrolizumab via frequency and severity of treatment-emergent adverse events (TEAE) via CommonTerminology Criteria for Adverse Events (CTCAE, v5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective radiographic response</measure>
    <time_frame>24 months</time_frame>
    <description>Patients achieving complete response (CR) or partial response (PR) via protocol-specified response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients achieving stable disease (SD), CR or PR via protocol-specified response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of radiographic response</measure>
    <time_frame>24 months</time_frame>
    <description>Duration of radiographic response (initial response to confirmed progression)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable radiographic response</measure>
    <time_frame>24 months</time_frame>
    <description>Radiographic response that persists for ≥ 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
    <description>If calculable, progression free survival (PFS) will be estimated based on the time from PVSRIPO infusion to death or confirmed progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Overall and landmark survival assessed by the proportion of patients alive at ≥ 6, ≥ 12 and at 24 months post-PVSRIPO infusion esitmated by Kaplan-Meier methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Recurrent Glioblastoma</condition>
  <condition>Supratentorial Glioblastoma</condition>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>PVSRIPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVSRIPO</intervention_name>
    <description>PVSRIPO (5x10^7 TCID50) delivered intratumorally via convection enhanced delivery (CED).</description>
    <arm_group_label>PVSRIPO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Pembrolizumab (200 mg IV) given every 3 weeks.</description>
    <arm_group_label>PVSRIPO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years of age.

          2. Histologically confirmed, recurrent, supratentorial glioblastoma; progression of
             primary glioblastoma or transformation from a lower grade to a higher grade
             acceptable.

          3. Enhancing lesion ≥1 cm shortest diameter to ≤ 5.5 cm longest diameter in all planes.

          4. Neurosurgical investigator must confirm placement of infusion catheter within or
             through the progressive enhancing tumor is feasible and at a safe distance relative to
             eloquent brain function, with the tip of the catheter being placed:

               1. Within the enhancing portion or in the vicinity of enhancement of target lesion
                  (ie, infiltrative disease).

               2. ≥ 0.5 cm from ventricles.

               3. ≥ 1 cm deep into the brain.

               4. ≥ 0.5 cm from corpus callosum.

          5. First or second relapse supported by MRI or CT scan; relapse is defined as progression
             following initial/prior therapy(ies).

          6. Failed previous first line therapy: maximum surgical resection and radiotherapy (RT)
             (plus concomitant chemotherapy followed by maintenance chemotherapy if unknown or
             methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter). Patients who begin
             but do not complete chemotherapy/RT may still be considered for eligibility at the
             discretion of Sponsor.

          7. Karnofsky Performance Status ≥ 70 at screening and baseline.

          8. Undergone prior vaccination against PV and received a boost immunization with
             trivalent inactivated poliovirus vaccine (IPOL®) at least 1 week, but less than 6
             weeks, prior to administration of PVSRIPO. Note: Patients who are unsure of their
             prior vaccination status/who have not been vaccinated must provide proof of
             vaccination and/or evidence of anti-PV immunity prior to enrollment, as applicable.

          9. Ability to safely discontinue anti-coagulant therapy(ies) prior to biopsy/catheter
             placement, as required per site/surgical guidelines.

         10. Hemoglobin ≥ 9 g/dL prior to biopsy/catheter placement.

         11. Platelet count ≥ 100,000/μL (unsupported); ≥ 125,000/ μL (can be supported via
             platelet transfusion) at biopsy/catheter placement.

         12. ANC ≥ 1000/μL prior to biopsy/catheter placement.

         13. Creatinine ≤ 1.2 x ULN prior to biopsy/catheter placement.

         14. Total bilirubin, ALT, AST, ALP ≤ 2.5 x ULN prior to biopsy/catheter placement.

         15. PT and aPTT ≤ 1.2 x ULN prior to biopsy/catheter placement.

         16. If undetectable ATT IgG at screen, Tdap booster vaccine ≥ 1 week prior to
             biopsy/catheter placement.

         17. Patients must be willing and able to understand and provide written informed consent.

        Exclusion Criteria:

          1. Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
             anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically
             targeting T-cell co-stimulation or checkpoint pathways) ≤ 12 weeks prior to PVSRIPO
             infusion. Note: Patients who permanently discontinued any of the above therapies for
             severe or life-threatening immune-related reactions are excluded.

          2. Excluded are:

               1. Neoplastic lesions in the brainstem, cerebellum, or spinal cord.

               2. Radiological evidence of active/growing multifocal disease: no size increase &gt;
                  0.5 cm in any direction on 2 consecutive MRI at least 3 months apart of any other
                  enhancing nontarget lesions present at baseline.

               3. Tumors with ≥ 1cm of contrast-enhancing tumor component crossing the midline
                  (crossing the corpus callosum).

               4. Extensive subependymal disease: multiple lesions or lesions covering &gt; 50% of
                  subependymal space. Tumor touching subependymal space allowed.

               5. Extensive leptomeningeal disease: multiple lesions or lesions covering &gt; 50% of
                  leptomeninges. Tumor touching leptomeninges allowed.

          3. Systemic immunosuppressive treatments other than systemic corticosteroids (eg,
             methotrexate, chloroquine, azathioprine) within six months of PVSRIPO infusion.

          4. Requires treatment with high dose systemic corticosteroids, defined as dexamethasone &gt;
             4 mg/day or equivalent, within 2 weeks of PVSRIPO infusion.

          5. Prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or
             therapeutics delivered by local injection or CED, including PVSRIPO.

          6. Pregnant and/or breast feeding female; patient/female partner of childbearing
             potential who is unwilling to utilize protocol-defined acceptable form of
             contraception for duration of study.

          7. Impending/life-threatening cerebral herniation syndrome, per neurosurgeon/designate.

          8. Severe, active co-morbidity, defined as follows:

               1. Infection requiring IV treatment/unexplained febrile illness (Tmax &gt;
                  99.5°F/37.5°C).

               2. Known immunosuppressive disease/human immunodeficiency virus infection

               3. Known active hepatitis B or C infection via positive viral DNA or RNA,
                  respectively.

               4. Unstable or severe intercurrent medical conditions such as severe heart disease
                  (New York Heart Association Class 3 or 4).

               5. Known lung disease with forced expiratory volume in 1st second of expiration &lt;
                  50%.

               6. Uncontrolled diabetes mellitus (eg, hemoglobin A1C level &gt; 7.0% with treatment).

          9. Known albumin allergy.

         10. Uncontrolled unexplained bleeding and/or hemoptysis within 4 weeks of planned PVSRIPO
             infusion.

         11. Inability to undergo brain MRI with and without contrast. History of
             severe/anaphylactic reaction to gadolinium contrast agent is excluded. Mild allergy
             (eg, rash) acceptable with prophylactic acetaminophen and diphenhydramine.

         12. History of neurological complications due to PV infection.

         13. Not recovered from toxic side effects (alopecia acceptable) and/or no current or prior
             tumor treatments within the following timeframe relative to biopsy/catheter placement:

               1. Chemotherapy or bevacizumab ≤ 4 weeks (except for nitrosourea (6 weeks) or
                  metronomic dosed chemotherapy/targeted therapies such as daily temozolomide,
                  etoposide or cyclophosphamide (1 week)).

               2. Tumor treating fields ≤ 7 days.

               3. RT of brain ≤ 12 weeks, except for progressive disease outside of the radiation
                  field or 2 progressive scans at least 4 weeks apart or histopathologic
                  confirmation.

         14. History of agammaglobulinemia.

         15. Known hypersensitivity to pembrolizumab, or any components of pembrolizumab.

         16. Active autoimmune disease requiring systemic immunomodulatory treatment within the
             past 12 months; physiologic replacement therapy (eg, thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency)
             is not considered a form of systemic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa Franklin</last_name>
    <phone>919-241-7509</phone>
    <email>lfranklin@istarioncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea True Kelly, PhD</last_name>
    <phone>919-241-7509</phone>
    <email>atkelly@istarioncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

